Clinical trials: Stasis Ulcer
Venous Thromboses, Venous Disease
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for…
- Conditions
- Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis
- Trial name
- NCT05409976
- Testing
- GORE® VIAFORT Vascular Stent
- Where
- 17 sites in United States, Australia and 5 more
- Volunteers
- 136 people
- Sponsor
- W.L.Gore & Associates
Venous Leg Ulcer, Venous Stasis Ulcer
Safety Follow-Up to HP 802-247-09-015
This is a 24-week observational follow safety study for Study 802-247-09-015.
- Trial name
- NCT00900029
- Testing
- No HP802 Treatment, No HP802 Vehicle Treatment
- Where
- 30 sites in United States, Canada
- Volunteers
- 206 people
- Sponsor
- Healthpoint
Venous Leg Ulcer, Chronic Venous Insufficiency
Evaluation of a Dual Action Pneumatic Compression System: Tolerance and Comfort in Patients With Venous Leg Ulcers (VLUs)
The purpose of the study is to assess treatment tolerance and comfort in chronic VLUs after 4 weeks of treatment using a dual action pneumatic compression device.
- Conditions
- Venous Leg Ulcer, Chronic Venous Insufficiency, Venous Stasis Ulcer, Venous Ulcer
- Trial name
- NCT02395302
- Testing
- Dual Action Pneumatic Compression
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Tactile Medical
Venous Stasis Ulcers
Wound Fluid Protease Levels During Use of Novel Wound Dressing
This study is being conducted to characterize the way leg wounds respond to a new type of wound dressing, compared to wounds in patients who are not using the new dressing.
- Trial name
- NCT01567150
- Testing
- Novel Dressing
- Where
- 8 sites in United States
- Volunteers
- 35 people
- Sponsor
- Hollister Incorporated
Venous Leg Ulcer, Venous Stasis Ulcers
Dose Finding Study of HP802-247 in Venous Leg Ulcers
This is a 16-week study for subjects with a venous leg ulcer between the knee and ankle. This research is being done to determine the effectiveness of two dosing frequencies and two different concentrations of HP802-247, together…
- Trial name
- NCT00852995
- Testing
- HP802-247
- Where
- 30 sites in United States, Canada
- Volunteers
- 228 people
- Sponsor
- Healthpoint
Venous Ulcer, Venous Stasis Ulcer
Safety and Efficacy Trial of HP802-247 in the Treatment of Chronic Venous Leg Ulcers
This study is being done to find out if an investigational product called HP802-247 can help people with venous leg ulcers. Investigational means that HP802-247 has not been approved by the U.S.
- Conditions
- Venous Ulcer, Venous Stasis Ulcer, Ulcer
- Trial name
- NCT01853384
- Testing
- HP802-247, HP802-247 Vehicle
- Where
- 46 sites in Belgium, Czechia and 3 more
- Volunteers
- 252 people
- Sponsor
- Healthpoint
Venous Stasis Ulcer
Efficacy Study of the Application of Low Level Laser Light to Treat Venous Stasis Ulcers
The purpose of this study is to determine whether low level laser light therapy is effective as an adjunctive therapy to the healing of venous stasis leg ulcers.
- Trial name
- NCT01376050
- Testing
- Erchonia ML Scanner (MLS)
- Where
- 2 sites in United States, France
- Volunteers
- 24 people
- Sponsor
- Erchonia Corporation
Diabetic Foot Ulcers (DFU), Venous Stasis Ulcers (VSU)
OASIS Wound Matrix (Oasis) Mechanism of Action
OASIS Wound Matrix (Oasis) will be applied to wounds, with sequential biopsy of healing wounds to explore the mechanism of action.
- Trial name
- NCT00570141
- Testing
- OASIS Wound Matrix
- Where
- 3 sites in United States
- Volunteers
- 13 people
- Sponsor
- Healthpoint
Venous Stasis Ulcers
Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers
The purpose of this study is to evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Venous Stasis ulcers
- Trial name
- SSVS (NCT00832091)
- Testing
- Thymosin Beta 4
- Where
- 8 sites in Italy, Poland
- Volunteers
- 72 people
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.